Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

apital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's therapeutic focus is oncology, but is also developing therapeutic products for inflammation, metabolic, and infectious diseases, as well as for the treatment of chronic pain. Sorrento's proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutics. In addition, Sorrento is developing proprietary Antibody Drug Conjugates as well as Antibody formulated Drug Conjugates combining its G-MAB® antibodies with anti-tumor agents.

More information is available at www.sorrentotherapeutics.com.

Forward-Looking Statements
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sor
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... TORONTO , Aug. 21, 2014 /CNW/ - Bedrocan ... appointed three independent members to its Board of ... care experience of the company, a leading licensed ... . Internationally, Bedrocan has 13 years, experience ... patients in seven countries, including Canada. ...
(Date:8/21/2014)... 21, 2014   Auxilium Pharmaceuticals, Inc. ... company, today announced positive results from a randomized, ... (or CCH) for the treatment of edematous fibrosclerotic ... Phase 2a trial, all three doses of CCH ... an improvement in the appearance of cellulite as ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
(Date:8/22/2014)... Dr Murray Grossan was interviewed for an article in ... October 2014 issue of Bottom Line Personal magazine, there will ... treating snoring, and in some cases Obstructive Sleep Apnea. ... adults snore occasionally, and about 25% do it all the ... the back of the throat tend to sag when you ...
(Date:8/21/2014)... 22, 2014 Benefiting from accelerated ... medical expenses, the Chinese orthopedic instrument market demand ... a CAGR of 19.2% during 2009-2013. Trauma products, ... segments of orthopedic instruments in China, of which ... share in 2013. , Being optimistic about bright ...
(Date:8/21/2014)... 2014 Strongly influenced by their ... when there are no consequences, researchers in Georgia ... , This could imply that humans are less ... others, researchers said. Their findings are published in ... sense of unfairness is affected by their self-interest, ...
(Date:8/21/2014)... August 21, 2014 Local agencies in ... larger discounts for specific protection plans, according to released ... consumers to quote life insurance from local agencies using ... local agents that appear inside of the national system ... method of price reviews this year. Adults who enter ...
(Date:8/21/2014)... 22, 2014 The “Proteomics Market ... Chromatography, Electrophoresis, Surface Plasmon Resonance, X-ray Crystallography) - ... 2018", analyzes and studies the major market drivers, ... and the Rest of the World (RoW) , ... through 415 pages and in-depth TOC on “Proteomics ...
Breaking Medicine News(10 mins):Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 3Health News:China Orthopedic Instrument Industry Report, 2014-2017 Now Available at ChinaMarketResearchReports.com 2Health News:China Orthopedic Instrument Industry Report, 2014-2017 Now Available at ChinaMarketResearchReports.com 3Health News:China Orthopedic Instrument Industry Report, 2014-2017 Now Available at ChinaMarketResearchReports.com 4Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 2Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 5
... in births of autistic children have led to a fear ... towards an autistic epidemic. However a recent report, which was ... out that this is not true. The report points out ... autistic epidemic., ,The study had pointed out that recent ...
... size at birth, as a marker of an adverse ... // death from cardiovascular disease, according to the study ... obtained by studying 13830 individuals born between 1924 and ... causes of death between 1971 and 1998 was obtained ...
... Aptivus ( tipranavir ) , has been recently approved ... are to be given in combination with ritonavir for treatment ... for patients with advanced HIV disease, and provides a new ... of Aptivus in combination with ritonavir, has shown to be ...
... to varying degrees of energy loss during aerobic exercises and ... our bodies react to exercise programs is genetic in origin ... level of blood glucose in the body etc. ,According ... Washington University School of Medicine, exercise can help the scientists ...
... India ,German Remedies, a part of the Zydus group, has ... lymphocytic leukemia. Chronic Lymphocytic Leukemia (CLL) is a cancer of ... present has no cure. The disease is unknown in childhood, ... with increasing age. ,Fludarabine has emerged as one ...
... of the smokers reveals that the smokers may differ in ... to smoking. ,Researchers have found that the urge to ... according to the brain responses to the smoking habit. Researchers ... brain images of smokers in a bid to study the ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: